Developer docs
API playgroundTry for free, no card

Search company profiles

Deepcell

Full company profile

uuid00002f3

Namestring
Deepcell
Legal namestring
Deepcell, Inc.
Websiteurl
deepcell.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Deepcell is a venture-backed life sciences company founded in 2017 as a spinout from Stanford University, headquartered in Menlo Park, California. The company develops and commercializes the REM-I platform, an AI-powered single-cell analysis and sorting system that combines high-resolution brightfield imaging (0.16 µm/pixel resolution, capturing up to 1,000 cells per second), gentle microfluidics, and a proprietary self-supervised deep learning model called the Human Foundation Model (HFM). The HFM extracts 115-dimensional morphological embeddings from brightfield cell images without requiring labels, stains, or destructive sample preparation, enabling researchers to classify and sort live cells based on visual phenotypes alone — an approach Deepcell brands as "morpholomics." The platform is complemented by the AXON Data Suite for cloud or on-premises data exploration and visualization, with an air-gapped REM-I OnSite variant available for regulated and data-sovereign environments.

Deepcell sells its instruments primarily through direct enterprise field sales to pharmaceutical companies, academic research institutions, and biotech firms, with a "Request a demo" motion on its website. Revenue is generated through three streams: capital equipment sales of the REM-I instrument, subscription licensing of the AXON software, and recurring sales of reagents and consumables. Pricing is quote-based and not publicly disclosed. The company is expanding commercially into international markets including China, supported by the OnSite deployment architecture for data localization. Named application areas span oncology research, pharmaceutical drug discovery, cell and gene therapy QC, cell line development, and stem cell research, with early customer references from Erasmus Medical Center, Stanford, UCSF, and Ingel Therapeutics. The company has raised approximately $98M+ across disclosed rounds, with a $73M Series B in March 2022 led by Koch Disruptive Technologies and a subsequent venture round in April 2025 led by 50Y (Fifty Years).

Short descriptiontext

Deepcell is a Stanford-spinout life sciences company that builds the REM-I platform, an AI-powered, label-free single-cell imaging and sorting system used by pharmaceutical companies, academic research institutions, and biotech firms to profile and isolate live cells based on high-dimensional morphological features.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMenlo Park, United States
HQ citystring
Menlo Park
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
single-cell analysis, label-free cell sorting, AI cell morphology, microfluidic cell enrichment, morpholomics platform
Industry1 code
PRIMARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments
NAICS code1 code
  • Analytical Laboratory Instrument Manufacturing334516
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
Life Sciences Instrumentation
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1REM-I Platform Sales
TypeHardware Sales
Description

Sale of the REM-I instrument platform for AI-powered single cell analysis and sorting. The platform is a high-value capital equipment for research institutions and pharmaceutical companies.

deepcell.com
2Software Licensing (AXON Data Suite)
TypeSubscription Recurring
Description

Software licensing for data analysis and visualization through the AXON Data Suite, available as cloud or on-premises deployment.

deepcell.com
3Reagents and Consumables
TypeSubscription Recurring
Description

Sale of reagents and consumables for the REM-I platform workflow.

deepcell.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Deepcell develops and sells the REM-I Platform, an integrated instrument that combines high-resolution brightfield imaging, AI-powered morphological analysis via its Human Foundation Model (HFM), and gentle label-free microfluidic sorting to classify and isolate single cells in real time. The platform is sold with the AXON Data Suite software for analysis and visualization, and is offered in a fully on-premises REM-I OnSite configuration for regulated environments. Reagents and consumables are sold alongside the instrument as recurring revenue.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over 1 million single-cell profiles generated per experiment
+3 more records
Product overview1 text field

Deepcell offers the REM-I Platform as its core product, a fully integrated cell analysis and enrichment system that combines high-resolution brightfield imaging, AI-powered morphological analysis via the Human Foundation Model (HFM), and gentle label-free sorting in a single workflow. The platform is complemented by the AXON Data Suite software for data visualization and analysis, and is available in two deployment configurations: the standard cloud-connected REM-I and REM-I OnSite for air-gapped, on-premises use in regulated environments. Deepcell also pioneered Morpholomics, a label-free approach to studying cell morphology as a high-dimensional biological readout, and is developing GenAI capabilities to interpret the HFM latent space and integrate with other omics modalities.

Product and service3 records
1REM-I Platform
CategorySingle-cell analysis instrumentation
Description

A fully integrated AI-powered cell analysis and sorting platform that combines high-resolution brightfield imaging (0.16 µm/pixel), the Human Foundation Model for real-time morphological analysis, and gentle label-free microfluidic sorting to classify and isolate viable single cells in one workflow. Targeted at pharmaceutical companies, academic research institutions, and biotech firms conducting drug discovery, oncology research, cell therapy QC, and basic cell biology.

2REM-I OnSite
CategoryOn-premises single-cell analysis deployment
Description

An air-gapped, on-premises deployment configuration of Deepcell's AXON Data Suite software that runs entirely on the REM-I instrument with no cloud dependency. Designed for pharmaceutical organizations with stringent data governance policies, GxP-regulated facilities, and international placements requiring data sovereignty, enabling complete run management, analysis, and visualization while keeping all data local.

3AXON Data Suite
CategoryData analysis and visualization software
Description

Integrated cloud and on-premises software solution for exploring, analyzing, visualizing, and managing data and runs from the REM-I platform. Enables annotation of cells and morphotypes, stores and reviews single-cell images, and provides two-way communication with the REM-I instrument for image capture and sorting. Targeted at research scientists and bioinformaticians using the REM-I platform in pharmaceutical and academic settings.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Deepcell originated from Stanford University research labs and was spun out from Stanford in 2017. Ongoing relationship with Stanford researchers including Scientific Advisory Board member Euan Ashley and continued collaboration on research.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

10x Genomics is a leading provider of single-cell analysis instruments and consumables (Chromium, Visium, Xenium). It is the most direct competitor to Deepcell in single-cell profiling workflows for pharma and academic research.

TypeDirect peer
Description

Cytek provides advanced flow cytometry and cell sorting instruments used widely in immunology, oncology, and cell therapy research. Its spectral flow platforms overlap with Deepcell's cell phenotyping and sorting use cases.

TypeDirect peer
Description

Standard BioTools offers mass cytometry and microfluidic single-cell analysis platforms (Hyperion, CyTOF). It competes with Deepcell in high-dimensional single-cell profiling for translational research.

TypeDirect peer
Description

PhenomeX (formerly Berkeley Lights) operates the Beacon optofluidic platform for single-cell functional screening and sorting, overlapping with Deepcell's label-free cell isolation and screening applications in cell therapy and antibody discovery.

TypeDirect peer
Description

Mission Bio provides single-cell multi-omics platforms (Tapestri) for genomics and proteomics at single-cell resolution, targeting oncology and pharma applications that overlap with Deepcell's translational research customer base.

TypeBroad incumbent
Description

BD is a global life sciences incumbent offering flow cytometry instruments, cell sorters (FACSDiva), and reagents used across pharma and academic labs. It competes with Deepcell broadly in cell analysis but as part of a much larger portfolio.

TypeBroad incumbent
Description

Bio-Techne provides a broad portfolio of life science reagents, assays, and analytical tools (including the ProteinSimple and ExoDx brands). Its cell biology and proteomics offerings overlap with Deepcell's translational and cell therapy research use cases.

TypeEmerging player
Description

Parse Biosciences offers scalable single-cell sequencing kits (Evercode) used in pharma and academic research. It competes with Deepcell indirectly by providing an alternative single-cell readout workflow.

TypeBroad incumbent
Description

Bruker, through its acquisition of NanoString's spatial biology assets, offers high-plex spatial omics platforms that overlap with Deepcell's emerging multi-omics ambitions in translational research.

10Sony Biotechnology
TypeRegional player
Description

Sony Biotechnology markets cell sorters and flow cytometry analyzers (MA900, SH800) used in research and cell therapy manufacturing, competing with Deepcell in label-free and gentle cell sorting workflows.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Deepcell

Life Sciences Instrumentationdeepcell.com

Deepcell is a Stanford-spinout life sciences company that builds the REM-I platform, an AI-powered, label-free single-cell imaging and sorting system used by pharmaceutical companies, academic research institutions, and biotech firms to profile and isolate live cells based on high-dimensional morphological features.

What Deepcell does

Deepcell is a venture-backed life sciences company founded in 2017 as a spinout from Stanford University, headquartered in Menlo Park, California. The company develops and commercializes the REM-I platform, an AI-powered single-cell analysis and sorting system that combines high-resolution brightfield imaging (0.16 µm/pixel resolution, capturing up to 1,000 cells per second), gentle microfluidics, and a proprietary self-supervised deep learning model called the Human Foundation Model (HFM). The HFM extracts 115-dimensional morphological embeddings from brightfield cell images without requiring labels, stains, or destructive sample preparation, enabling researchers to classify and sort live cells based on visual phenotypes alone — an approach Deepcell brands as "morpholomics." The platform is complemented by the AXON Data Suite for cloud or on-premises data exploration and visualization, with an air-gapped REM-I OnSite variant available for regulated and data-sovereign environments.

Deepcell sells its instruments primarily through direct enterprise field sales to pharmaceutical companies, academic research institutions, and biotech firms, with a "Request a demo" motion on its website. Revenue is generated through three streams: capital equipment sales of the REM-I instrument, subscription licensing of the AXON software, and recurring sales of reagents and consumables. Pricing is quote-based and not publicly disclosed. The company is expanding commercially into international markets including China, supported by the OnSite deployment architecture for data localization. Named application areas span oncology research, pharmaceutical drug discovery, cell and gene therapy QC, cell line development, and stem cell research, with early customer references from Erasmus Medical Center, Stanford, UCSF, and Ingel Therapeutics. The company has raised approximately $98M+ across disclosed rounds, with a $73M Series B in March 2022 led by Koch Disruptive Technologies and a subsequent venture round in April 2025 led by 50Y (Fifty Years).

Deepcell firmographics

Firmographics
Name
Deepcell
Legal name
Deepcell, Inc.
Website
https://deepcell.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Deepcell is a Stanford-spinout life sciences company that builds the REM-I platform, an AI-powered, label-free single-cell imaging and sorting system used by pharmaceutical companies, academic research institutions, and biotech firms to profile and isolate live cells based on high-dimensional morphological features.
Ownership category
akta.pro rank

Deepcell industry classification

Industry
Product category
Life Sciences Instrumentation
NAICS
Analytical Laboratory Instrument Manufacturing (334516)
SIC
Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments

Keywords

  • Single-cell analysis
  • Label-free cell sorting
  • AI cell morphology
  • Microfluidic cell enrichment
  • Morpholomics platform

Where Deepcell is headquartered

Location

Headquarters

HQ city
Menlo Park
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Deepcell business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. REM-I Platform Sales: Sale of the REM-I instrument platform for AI-powered single cell analysis and sorting. The platform is a high-value capital equipment for research institutions and pharmaceutical companies.
  2. Software Licensing (AXON Data Suite): Software licensing for data analysis and visualization through the AXON Data Suite, available as cloud or on-premises deployment.
  3. Reagents and Consumables: Sale of reagents and consumables for the REM-I platform workflow.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Deepcell product offering

Product offering

Core offering

Deepcell develops and sells the REM-I Platform, an integrated instrument that combines high-resolution brightfield imaging, AI-powered morphological analysis via its Human Foundation Model (HFM), and gentle label-free microfluidic sorting to classify and isolate single cells in real time. The platform is sold with the AXON Data Suite software for analysis and visualization, and is offered in a fully on-premises REM-I OnSite configuration for regulated environments. Reagents and consumables are sold alongside the instrument as recurring revenue.

Product overview

Deepcell offers the REM-I Platform as its core product, a fully integrated cell analysis and enrichment system that combines high-resolution brightfield imaging, AI-powered morphological analysis via the Human Foundation Model (HFM), and gentle label-free sorting in a single workflow. The platform is complemented by the AXON Data Suite software for data visualization and analysis, and is available in two deployment configurations: the standard cloud-connected REM-I and REM-I OnSite for air-gapped, on-premises use in regulated environments. Deepcell also pioneered Morpholomics, a label-free approach to studying cell morphology as a high-dimensional biological readout, and is developing GenAI capabilities to interpret the HFM latent space and integrate with other omics modalities.

Differentiator

Problem solved

Functional benefit

Products and services

  • REM-I Platform A fully integrated AI-powered cell analysis and sorting platform that combines high-resolution brightfield imaging (0.16 µm/pixel), the Human Foundation Model for real-time morphological analysis, and gentle label-free microfluidic sorting to classify and isolate viable single cells in one workflow. Targeted at pharmaceutical companies, academic research institutions, and biotech firms conducting drug discovery, oncology research, cell therapy QC, and basic cell biology.
  • REM-I OnSite An air-gapped, on-premises deployment configuration of Deepcell's AXON Data Suite software that runs entirely on the REM-I instrument with no cloud dependency. Designed for pharmaceutical organizations with stringent data governance policies, GxP-regulated facilities, and international placements requiring data sovereignty, enabling complete run management, analysis, and visualization while keeping all data local.
  • AXON Data Suite Integrated cloud and on-premises software solution for exploring, analyzing, visualizing, and managing data and runs from the REM-I platform. Enables annotation of cells and morphotypes, stores and reviews single-cell images, and provides two-way communication with the REM-I instrument for image capture and sorting. Targeted at research scientists and bioinformaticians using the REM-I platform in pharmaceutical and academic settings.

Quantifiable outcome

  • Over 1 million single-cell profiles generated per experiment
  • +3 more outcomes

Companies that use Deepcell

Customer profile

Named customers4 records

Segments5 records

Ideal customer profiles3 records

Deepcell technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Deepcell partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Stanford UniversitycoreStrategic or Co-development PartnerDeepcell originated from Stanford University research labs and was spun out from Stanford in 2017. Ongoing relationship with Stanford researchers including Scientific Advisory Board member Euan Ashley and continued collaboration on research.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Deepcell competitors and assessment

Company assessment

Direct peers

  • 10x Genomics: 10x Genomics is a leading provider of single-cell analysis instruments and consumables (Chromium, Visium, Xenium). It is the most direct competitor to Deepcell in single-cell profiling workflows for pharma and academic research.
  • Cytek Biosciences: Cytek provides advanced flow cytometry and cell sorting instruments used widely in immunology, oncology, and cell therapy research. Its spectral flow platforms overlap with Deepcell's cell phenotyping and sorting use cases.
  • Standard BioTools (formerly Fluidigm): Standard BioTools offers mass cytometry and microfluidic single-cell analysis platforms (Hyperion, CyTOF). It competes with Deepcell in high-dimensional single-cell profiling for translational research.
  • Berkeley Lights (now PhenomeX): PhenomeX (formerly Berkeley Lights) operates the Beacon optofluidic platform for single-cell functional screening and sorting, overlapping with Deepcell's label-free cell isolation and screening applications in cell therapy and antibody discovery.
  • Mission Bio: Mission Bio provides single-cell multi-omics platforms (Tapestri) for genomics and proteomics at single-cell resolution, targeting oncology and pharma applications that overlap with Deepcell's translational research customer base.

Broad incumbents

  • Becton, Dickinson and Company (BD): BD is a global life sciences incumbent offering flow cytometry instruments, cell sorters (FACSDiva), and reagents used across pharma and academic labs. It competes with Deepcell broadly in cell analysis but as part of a much larger portfolio.
  • Bio-Techne: Bio-Techne provides a broad portfolio of life science reagents, assays, and analytical tools (including the ProteinSimple and ExoDx brands). Its cell biology and proteomics offerings overlap with Deepcell's translational and cell therapy research use cases.
  • Bruker (NanoString-acquired spatial biology): Bruker, through its acquisition of NanoString's spatial biology assets, offers high-plex spatial omics platforms that overlap with Deepcell's emerging multi-omics ambitions in translational research.

Emerging players

  • Parse Biosciences: Parse Biosciences offers scalable single-cell sequencing kits (Evercode) used in pharma and academic research. It competes with Deepcell indirectly by providing an alternative single-cell readout workflow.

Regional players

  • Sony Biotechnology: Sony Biotechnology markets cell sorters and flow cytometry analyzers (MA900, SH800) used in research and cell therapy manufacturing, competing with Deepcell in label-free and gentle cell sorting workflows.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Deepcell social profiles

Digital presence

Deepcell financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Deepcell leadership team

Management profile

Number of profiles

Profiles10 records

Deepcell funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Deepcell M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Deepcell

What does Deepcell do?

Deepcell develops and sells the REM-I Platform, an integrated instrument that combines high-resolution brightfield imaging, AI-powered morphological analysis via its Human Foundation Model (HFM), and gentle label-free microfluidic sorting to classify and isolate single cells in real time. The platform is sold with the AXON Data Suite software for analysis and visualization, and is offered in a fully on-premises REM-I OnSite configuration for regulated environments. Reagents and consumables are sold alongside the instrument as recurring revenue.

Is Deepcell a public or private company?

Deepcell is a private company. It is classified as venture growth investor backed and is currently operating.

When was Deepcell founded?

Deepcell was founded in 2017. It employs 11 to 50 people.

Where is Deepcell based?

Deepcell is headquartered in Menlo Park, United States, in the North America region.

How does Deepcell make money?

Three revenue lines are on record. REM-I Platform Sales are the primary driver. The others are software Licensing (AXON Data Suite) and reagents and Consumables.

Who are Deepcell's main competitors?

Direct peers on record are 10x Genomics, Cytek Biosciences, Standard BioTools (formerly Fluidigm), Berkeley Lights (now PhenomeX) and Mission Bio. Broad incumbents are Becton, Dickinson and Company (BD), Bio-Techne and Bruker (NanoString-acquired spatial biology). Parse Biosciences is listed as an emerging player. Sony Biotechnology is listed as a regional player.

Does Deepcell have an API?

No public API is recorded for Deepcell.

What industry is Deepcell in?

Deepcell's product category is Life Sciences Instrumentation. Its primary akta.pro industry code is HLAGAIAE, Microscopy, Imaging & Flow Cytometry Instruments. Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketScreenerDeepcell, Inc. announced that it has received CNY 100 million in funding from Beijing Shunxi Venture Capital Fund Management Co.,Ltd., Casstar Technology Investment Co., Ltd., Cenova Capital, TopViewDeepcell, Inc. announced that it has received CNY 100 million in funding from Beijing Shunxi Venture Capital Fund Management Co., Ltd., Casstar Technology Investment Co., Ltd., Cenova Capital, and TopView Chart Zero2IPO Holdings Inc. The investment marks a significant capital injection for Deepcell to support its operational growth and strategic initiatives.EIN PresswireDeepcell Appoints Janette Phi as Chief Business Officer, Raises Venture Round, and Expands to New Menlo Park HQDeepcell appointed Janette Phi as Chief Business and Commercial Officer and closed an initial venture round led by 50Y VC. The funding will support commercialization of its REM-I platform and expansion of its AI model and cloud software. The company also relocated its headquarters to Menlo Park to support growth.BioSpaceDeepcell Announces Successful Installation of the First Commercial REM-I PlatformDeepcell announced the first commercial placement of its REM-I platform at Erasmus Medical Center in Rotterdam, following previous beta testing phases. The company plans to present new customer data and experiences from this platform at the CYTO 2024 and Immunology 2024 scientific conferences.YahooDeepcell Delivers Final Beta Testing Instruments Ahead of Full REM-I Platform LaunchDeepcell announced its REM-I platform beta program, with selected academic institutions in the U.S. and Europe testing the AI-powered single-cell analysis system. The platform will study plasma disorders, blood cancers, and other cellular processes, with full commercialization planned next quarter.DrugdiscoverytrendsDeepcell aims to reboot cell analysis with AI and microfluidicsDeepcell, an AI-powered cell analysis company, has raised nearly $100 million, including a $73 million Series B and a $20 million Series A. The company, co-founded by Maddison Masaeli, partnered with NVIDIA and is launching its REM-I platform for label-free cell phenotyping. It also plans to bring its first products to market.Pulse 2.0Deepcell Partners With NVIDIA To Utilize Generative AI In Single Cell ResearchDeepcell announced a research collaboration with NVIDIA to integrate generative AI and multimodal applications into its single-cell analysis technology. The partnership will co-develop algorithms for cell image analysis using NVIDIA Clara, aiming to advance morpholomics discovery. Deepcell plans to fully commercialize its REM-I platform in 2024.DrugdiscoverytrendsThe latest on NVIDIA's biotech AI pacts with Amgen and DeepcellNVIDIA announced renewed partnerships with Amgen and DeepCell to accelerate drug discovery and cell morphology research using generative AI. Amgen will deploy a powerful AI system named Freyja on NVIDIA DGX SuperPOD infrastructure at its Iceland headquarters to build a human diversity atlas, while DeepCell will utilize NVIDIA Clara technology to commercialize its single-cell imaging platform.Business Wire BlogDeepcell Garners Industry Recognition for Disruptive AI-Driven Approach to Single Cell Morphology AnalysisDeepcell announced two industry recognitions for its AI-driven single-cell morphology platform, REM-I, and plans to share datasets and demo the Axon data suite at upcoming scientific meetings. The REM-I platform was named Cell Imaging Product of the Year, and CEO Maddison Masaeli received a Life Science Catalyst Award.DrugdiscoverytrendsDeepcell launches morphology platform powered by AIDeepcell launched REM-I, an AI-powered platform for single-cell morphological analysis in drug discovery. The company raised $73 million in Series B funding led by Koch Disruptive Technologies. The platform uses a Human Foundation Model trained on 2 billion cell images to assess cell viability and therapy response.Bio-itworldDeepcell Releases Sample Datasets to Highlight Morphology-Driven DataDeepcell released three datasets from its high-throughput platform, including 28 melanoma samples and 11 lung tumor samples, totaling about 1.1 million cells. The label-free morphology data aims to help researchers explore high-dimensional single-cell data and identify cell populations difficult to detect with molecular markers.